Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

BB Biotech AG publishes its interim report

22.04.2022

Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2022, which covers the results of its business activities for the first three months of 2022.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2022 amounted to CHF 300 mn (profit of CHF 221 mn in the same period 2021). For an investment company, the results reflect the share price development of the companies held in the portfolio.

 The interim report as at March 31, 2022 is available under report.bbbiotech.ch/Q122 or www.bbbiotech.com.


For further information:

 Media Relations
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tel. +41 44 267 67 00
Tanja Chicherio, tch@bellevue.ch